Business Description
Firebrick Pharma Ltd
ISIN : AU0000197352
Compare
Compare
Traded in other countries / regions
FRE.Australia IPO Date
2022-01-28Description
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.82 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.76 | |||||
| Beneish M-Score | -5.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.48 | |||||
| 9-Day RSI | 70.06 | |||||
| 14-Day RSI | 69.48 | |||||
| 6-1 Month Momentum % | 34.21 | |||||
| 12-1 Month Momentum % | -74.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.17 | |||||
| Quick Ratio | 4.37 | |||||
| Cash Ratio | 3.67 | |||||
| Days Sales Outstanding | 23.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -7.15 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -257.8 | |||||
| Net Margin % | -254.63 | |||||
| FCF Margin % | -256.58 | |||||
| ROE % | -149.07 | |||||
| ROA % | -129.87 | |||||
| ROIC % | -960.21 | |||||
| ROC (Joel Greenblatt) % | -4937.72 | |||||
| ROCE % | -150.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.7 | |||||
| PB Ratio | 8.56 | |||||
| Price-to-Tangible-Book | 7.7 | |||||
| EV-to-EBIT | -2.69 | |||||
| EV-to-EBITDA | -2.7 | |||||
| EV-to-Revenue | 6.95 | |||||
| EV-to-FCF | -2.79 | |||||
| Price-to-Net-Current-Asset-Value | 7.7 | |||||
| Price-to-Net-Cash | 7.7 | |||||
| Earnings Yield (Greenblatt) % | -37.14 | |||||
| FCF Yield % | -33.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Firebrick Pharma Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 1.794 | ||
| EPS (TTM) (A$) | -0.027 | ||
| Beta | 0 | ||
| Volatility % | 139.13 | ||
| 14-Day RSI | 69.48 | ||
| 14-Day ATR (A$) | 0.005724 | ||
| 20-Day SMA (A$) | 0.06 | ||
| 12-1 Month Momentum % | -74.5 | ||
| 52-Week Range (A$) | 0.036 - 0.36 | ||
| Shares Outstanding (Mil) | 178.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Firebrick Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Firebrick Pharma Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Firebrick Pharma Ltd Frequently Asked Questions
What is Firebrick Pharma Ltd(ASX:FRE)'s stock price today?
The current price of ASX:FRE is A$0.08. The 52 week high of ASX:FRE is A$0.36 and 52 week low is A$0.04.
When is next earnings date of Firebrick Pharma Ltd(ASX:FRE)?
The next earnings date of Firebrick Pharma Ltd(ASX:FRE) is .
Does Firebrick Pharma Ltd(ASX:FRE) pay dividends? If so, how much?
Firebrick Pharma Ltd(ASX:FRE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers